Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spectra Study: OPL-0401 in Diabetic Retinopathy
NCT05393284Phase 2Active, not recruiting
- Sponsor
- Valo Health
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OPL-0401 in diabetic retinopathy (DR), sponsored by Valo Health. Started Aug 2022; status: active, not recruiting.
02
Drugs
OPL-0401
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05393284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393284.